The balance sheet exhibits significant instability, with total assets declining from $444.0 million in 2025Q3 to $181.0 million in 2026Q1, alongside a complete write-down of $250.1 million in goodwill.
| Total Current Assets | 18.38M | 11.23M | 3.17M | 4.84M | 4.42M | 1.61M | 1.84M | 635.5K |
| Cash & Short-Term Investments | 12.32M | 10.38M | 864.04K | 3.01M | 4.17M | 1.48M | 1.79M | 635.5K |
| Cash Only | 12.32M | 10.38M | 864.04K | 3.01M | 4.17M | 1.48M | 1.79M | 635.5K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 396.9K | 711.96K | 102.49K | 47.95K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 693.72 | 1.27K | - | - | - | - | - | - |
| Inventory | 457.71K | 645.27K | 1.87M | 1.71M | 185.8K | 121.99K | 0 | 0 |
| Days Inventory Outstanding | 387.25 | 381.45 | 880.86 | 699.96 | 103.61 | 1.55K | - | - |
| Other Current Assets | 5.21M | -7.17M | 250K | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 162.62M | 81.17K | 4.14M | 6.95M | 7.42M | 4.29M | 391.87K | 25.9K |
| Property, Plant & Equipment | 58.83K | 81.17K | 4.04M | 6.82M | 7.34M | 3.76M | 316.87K | 25.9K |
| Fixed Asset Turnover | 0.34x | 2.51x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 250.11M | 32.5K | 52.51K | 62.48K | 0 | 0 | 0 |
| Long-Term Investments | 404.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 162.56M | -250.11M | 72.2K | 76.06K | 12.37K | 529.86K | 75K | 0 |
| Total Assets | 181M | 269.08M | 7.31M | 11.79M | 11.84M | 5.9M | 2.23M | 661.4K |
| Asset Turnover | 0.00x | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 8352.87% | 3579.03% | -37.96% | -0.43% | 100.59% | 164.43% | 237.47% | - |
| Total Current Liabilities | 2.22M | 4.7M | 5.19M | 3.69M | 2.01M | 2.77M | 101.25K | 100.49K |
| Accounts Payable | 1.58M | 590.69K | 976.55K | 794.11K | 543.23K | 804.14K | 101.25K | 100.49K |
| Days Payables Outstanding | 534.07 | 349.19 | 460.57 | 325.22 | 302.91 | 10.23K | 3.35K | 3.46K |
| Short-Term Debt | 0 | 3.08M | 3.76M | 0 | 0 | 700.01K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 637.73K | 1.02M | 98.91K | 2.42M | 1.15M | 585K | 0 | 0 |
| Current Ratio | 8.28x | 2.39x | 0.61x | 1.31x | 2.20x | 0.58x | 18.18x | 6.32x |
| Quick Ratio | 8.08x | 2.25x | 0.25x | 0.85x | 2.11x | 0.54x | 18.18x | 6.32x |
| Cash Conversion Cycle | 546.9 | 1.31K | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 132K | 162K | 192K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 264K | 0 | 132K | 162K | 192K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.22M | 4.7M | 5.32M | 3.85M | 2.2M | 2.77M | 101.25K | 100.49K |
| Total Debt | 0 | 3.08M | 3.76M | 0 | 0 | 700.01K | 0 | 0 |
| Net Debt | -12.32M | -7.3M | 2.9M | -3.01M | -4.17M | -779.15K | -1.79M | -635.5K |
| Debt / Equity | 0.00x | 0.01x | 1.89x | - | - | 0.22x | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.78x | - | - | - | - | - | - | - |
| Interest Coverage | -2260.15x | -647.82x | -4.47x | - | -2.51x | -26.84x | - | - |
| Total Equity | 178.78M | 264.38M | 2M | 7.93M | 9.64M | 3.14M | 2.13M | 560.92K |
| Equity Growth % | 21469.05% | 13144.64% | -74.84% | -17.7% | 207.41% | 47.18% | 279.88% | - |
| Book Value per Share | 2.46 | 10.45 | 476.74 | 4019.40 | 7857.48 | 2257.88 | 1534.07 | 403.83 |
| Total Shareholders' Equity | 178.78M | 264.38M | 2M | 7.93M | 9.64M | 3.14M | 2.13M | 560.92K |
| Common Stock | 4.03K | 2.9K | 205 | 1.53K | 941 | 519 | 460 | 1.38K |
| Retained Earnings | -403.19M | -316.95M | -34.45M | -25.15M | -15.31M | -10.67M | -6M | -3.66M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 23.29K | 591.81K | 214.25K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital exhaustion and dilution
As reported in recent financial filings, the company's total assets fluctuated from $181.0 million in 2026Q1 down from $444.0 million in 2025Q3, signaling a highly unstable capital base that appears to be struggling to find a sustainable equilibrium for its early-stage medical device operations.
The dramatic swings in asset levels suggest that the company is undergoing significant balance sheet restructuring or revaluation, which may indicate underlying uncertainty regarding the carrying value of its assets. Investors should monitor whether this volatility stems from asset impairment or erratic capital raising activities that fail to provide a stable foundation for growth.
Based on the company's reported figures, the current ratio of 8.28 in 2026Q1 masks a precarious cash position, as the firm's cash reserves of $12.3 million are being rapidly depleted by persistent operating losses and a lack of meaningful revenue generation to offset ongoing burn.
While the high current ratio might appear favorable at first glance, it likely reflects a lack of significant short-term liabilities rather than a robust liquidity position. The company's reliance on its remaining cash balance to fund operations suggests that liquidity will continue to tighten unless a major commercial breakthrough occurs.
According to the provided balance sheet data, the company's retained earnings have plummeted to -$403.2 million as of 2026Q1, indicating that historical capital has been largely consumed by operating deficits rather than being reinvested into productive, value-accretive assets for the business.
The erosion of equity highlights the significant value destruction that has occurred as the company attempts to commercialize its technology. This trend suggests that future growth may require further dilutive financing, which could continue to pressure shareholder value in the absence of a clear path to profitability.
As evidenced by the dramatic shift in goodwill from $250.1 million in 2025Q4 to zero in 2026Q1, the company's balance sheet appears highly sensitive to accounting adjustments that may obscure the true economic value of its intangible assets and intellectual property portfolio.
The sudden disappearance of goodwill warrants deep investigation, as it may indicate that previous acquisitions or internal valuations were significantly overstated. This volatility suggests that the book value of the company may not be a reliable indicator of its actual worth in a liquidation or acquisition scenario.
Quick answers to the most common questions about buying STSS stock.
As of 2025, Sharps Technology, Inc. (STSS) had total assets of $269.1M including $11.2M in current assets.
Sharps Technology, Inc. (STSS) carries total debt of $3.1M, offset by $10.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Sharps Technology, Inc. (STSS) has total shareholders' equity (book value) of $264.4M ($10.45 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Sharps Technology, Inc. (STSS) reported a current ratio of 2.39x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.